FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384339192> ?p ?o ?g. }

• W4384339192 endingPage "3625" @default.
• W4384339192 startingPage "3625" @default.
• W4384339192 abstract "Anti-SARS-CoV-2 mRNA vaccines can deeply affect cell-mediated immune responses in immunocompromised recipients, including cancer patients receiving active treatments. The clinical implications of changes in peripheral blood lymphocyte subsets following the third dose of mRNA-BNT162b2 vaccination (tozinameran) in patients on immune checkpoint blockade are not fully understood. We conducted a prospective analysis of the Vax-On-Third-Profile study to evaluate the impact of circulating lymphocyte dynamics on disease outcomes in this subgroup of patients.Recipients of booster dosing who had received before vaccination at least one course of an anti-PD-1/PD-L1 treatment for an advanced solid tumor were eligible. Immunophenotyping of peripheral blood was performed before the third dose of tozinameran (timepoint-1) and four weeks later (timepoint-2) to quantify the absolute counts of lymphocyte subpopulations, including CD3+CD4+ T cells, CD3+CD8+ T cells, B cells, and NK cells. Logistic regression was used to analyze the relationship between lymphocyte subsets and durable clinical benefit (DCB). The log-rank test and Cox regression model were applied to evaluate the relationship between lymphocyte subpopulations and both vaccine-related time-to-treatment failure (V-TTF) and overall survival (OS).We included a total of 56 patients with metastatic disease who were given a third dose of tozinameran between 23 September and 7 October 2021 (median age: 66 years; male: 71%). Most recipients had a diagnosis of lung cancer and were being treated with pembrolizumab or nivolumab. Compared to baseline, the third immunization resulted in an incremental change in the median counts of all lymphocyte subpopulations, which was statistically significant only for NK cells (p < 0.001). A significant correlation was found between NK cell counts and DCB at timepoint-2 (p < 0.001). Multivariate logistic regression analysis of DCB confirmed the predictive significance of high-level NK cell counts (p = 0.020). In multivariate Cox regression analysis, high-level NK cell counts independently predicted longer V-TTF [HR 0.34 (95% CI 0.14-0.80), p = 0.014] and OS [HR 0.36 (95% CI 0.15-0.89), p = 0.027].Our data suggest expansion of NK cell counts as the most noteworthy change in circulating lymphocytes after the third dose of tozinameran in cancer patients receiving PD-1/PD-L1-targeted agents. This change correlated with enhanced therapeutic efficacy, improving the rate of disease control, and prolonging survival outcomes. Similar findings have not been previously reported, implying that they have proof-of-concept value and warrant further confirmation." @default.
• W4384339192 created "2023-07-15" @default.
• W4384339192 creator A5000282306 @default.
• W4384339192 creator A5002147849 @default.
• W4384339192 creator A5004961191 @default.
• W4384339192 creator A5020421670 @default.
• W4384339192 creator A5034700088 @default.
• W4384339192 creator A5036641145 @default.
• W4384339192 creator A5045523492 @default.
• W4384339192 creator A5045603955 @default.
• W4384339192 creator A5048141257 @default.
• W4384339192 creator A5054422594 @default.
• W4384339192 creator A5071887801 @default.
• W4384339192 creator A5073273844 @default.
• W4384339192 creator A5086743021 @default.
• W4384339192 creator A5088057745 @default.
• W4384339192 creator A5088656498 @default.
• W4384339192 date "2023-07-14" @default.
• W4384339192 modified "2023-09-25" @default.
• W4384339192 title "Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study" @default.
• W4384339192 cites W1633547128 @default.
• W4384339192 cites W1976702412 @default.
• W4384339192 cites W2073300038 @default.
• W4384339192 cites W2576658154 @default.
• W4384339192 cites W2578528809 @default.
• W4384339192 cites W2738397398 @default.
• W4384339192 cites W2761154221 @default.
• W4384339192 cites W2768639020 @default.
• W4384339192 cites W2783760762 @default.
• W4384339192 cites W2890056446 @default.
• W4384339192 cites W2896352116 @default.
• W4384339192 cites W3030421220 @default.
• W4384339192 cites W3036393236 @default.
• W4384339192 cites W3080427029 @default.
• W4384339192 cites W3094862578 @default.
• W4384339192 cites W3097147331 @default.
• W4384339192 cites W3129727923 @default.
• W4384339192 cites W3133206057 @default.
• W4384339192 cites W3134837906 @default.
• W4384339192 cites W3139530191 @default.
• W4384339192 cites W3145657260 @default.
• W4384339192 cites W3174457883 @default.
• W4384339192 cites W3182898074 @default.
• W4384339192 cites W3184273969 @default.
• W4384339192 cites W3196370604 @default.
• W4384339192 cites W3197504359 @default.
• W4384339192 cites W3200303519 @default.
• W4384339192 cites W3205364181 @default.
• W4384339192 cites W3210768645 @default.
• W4384339192 cites W3211477370 @default.
• W4384339192 cites W4206717199 @default.
• W4384339192 cites W4210944007 @default.
• W4384339192 cites W4213371389 @default.
• W4384339192 cites W4220853018 @default.
• W4384339192 cites W4223544666 @default.
• W4384339192 cites W4224212891 @default.
• W4384339192 cites W4225492884 @default.
• W4384339192 cites W4225569559 @default.
• W4384339192 cites W4225607490 @default.
• W4384339192 cites W4226119258 @default.
• W4384339192 cites W4281396741 @default.
• W4384339192 cites W4281733207 @default.
• W4384339192 cites W4283019343 @default.
• W4384339192 cites W4283315173 @default.
• W4384339192 cites W4285405341 @default.
• W4384339192 cites W4285733788 @default.
• W4384339192 cites W4304734201 @default.
• W4384339192 cites W4306250626 @default.
• W4384339192 cites W4308027679 @default.
• W4384339192 cites W4308371705 @default.
• W4384339192 cites W4313312781 @default.
• W4384339192 cites W4320519460 @default.
• W4384339192 cites W4362558641 @default.
• W4384339192 cites W4366091046 @default.
• W4384339192 cites W4375955328 @default.
• W4384339192 doi "https://doi.org/10.3390/cancers15143625" @default.
• W4384339192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37509286" @default.
• W4384339192 hasPublicationYear "2023" @default.
• W4384339192 type Work @default.
• W4384339192 citedByCount "0" @default.
• W4384339192 crossrefType "journal-article" @default.
• W4384339192 hasAuthorship W4384339192A5000282306 @default.
• W4384339192 hasAuthorship W4384339192A5002147849 @default.
• W4384339192 hasAuthorship W4384339192A5004961191 @default.
• W4384339192 hasAuthorship W4384339192A5020421670 @default.
• W4384339192 hasAuthorship W4384339192A5034700088 @default.
• W4384339192 hasAuthorship W4384339192A5036641145 @default.
• W4384339192 hasAuthorship W4384339192A5045523492 @default.
• W4384339192 hasAuthorship W4384339192A5045603955 @default.
• W4384339192 hasAuthorship W4384339192A5048141257 @default.
• W4384339192 hasAuthorship W4384339192A5054422594 @default.
• W4384339192 hasAuthorship W4384339192A5071887801 @default.
• W4384339192 hasAuthorship W4384339192A5073273844 @default.
• W4384339192 hasAuthorship W4384339192A5086743021 @default.
• W4384339192 hasAuthorship W4384339192A5088057745 @default.
• W4384339192 hasAuthorship W4384339192A5088656498 @default.
• W4384339192 hasBestOaLocation W43843391921 @default.
• W4384339192 hasConcept C126322002 @default.

• next